Prolintane Stats & Data

Evidence synthesis: A double‑blind placebo‑controlled study in healthy volunteers using 10–20 mg oral prolintane found small cardiovascular changes relative to ephedrine but improved performance on a sign recording task at 2.5 h, consistent with NDRI‑type vigilance enhancement. Community reports consistently describe a narrow comfort window: low–moderate oral doses (≈10–50 mg) feel functional with mild euphoria, while higher/redosed amounts increase anxiety, vasoconstriction, tremor, and sweaty tunnel‑vision. Insufflation is commonly described as harsh on nasal mucosa with a sharper, shorter effect and more peripheral side‑effects; oral is favored for smoother onset. Users frequently remark on sexual arousal/pro‑sociality, compulsive redosing, and insomnia if taken late; repeating 40–60 mg oral doses the same day markedly worsens comedown discomfort. Structural and experiential similarity to pyrrolidine stimulants supports cross‑tolerance with α‑PVP/pyrovalerone‑like agents, though prolintane lacks the β‑keto group and tends to be milder/shorter. HR: identify substances via reagent/lab testing where available; dose accurately with a milligram scale; avoid late‑night redoses; monitor blood pressure/heart rate; maintain fluids and electrolytes; allow multi‑day breaks to reduce tolerance and compulsion; prefer oral route; avoid stimulant stacking and MAOIs; and treat unexpected chest pain, severe headache, or agitation as a medical issue. Legal status varies by jurisdiction; historically classified under ATC N06BX14 and not scheduled in Canada per 2012 Health Canada correspondence—always check current local law.